Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 57

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 57
---
 as a REIT for U.S. federal
income tax purposes commencing with our taxable year ended December 31, 2016.

Our common stock is listed on the NYSE under the
symbol “GMRE.” Our Series A Preferred Stock is listed on the NYSE under the symbol “GMRE PrA.” Our principal executive
offices are located at 7373 Wisconsin Avenue, Suite 800, Bethesda Maryland, 20814. Our telephone number is (202) 524-6851. Our website
is located at http://www.globalmedicalreit.com. The information found on, or otherwise accessible through, our website is not incorporated
into, and does not form a part of, this prospectus or any accompanying prospectus supplement or any other report or document we file with
or furnish to the SEC.

| 5 |

<div align='center'>Risk
Factors</div>

Before purchasing any securities offered by this
prospectus, you should carefully consider the risk factors incorporated by reference into this prospectus from our most recent Annual
Report on Form 10-K, the risks, uncertainties and additional information set forth in our SEC reports on Forms 10-K, 10-Q and 8-K and
in the other documents incorporated by reference into this prospectus, and any risks described in any accompanying prospectus supplement.
For a description of these reports and documents, and information about where you can find them, see “Where You Can Find More Information”
and “Incorporation by Reference of Information Filed with the SEC.” Additional risks not presently known or that are currently
deemed immaterial could also materially and adversely affect our financial condition, results of operations, business and prospects.

| 6 |

<div align='center'>Use
of Proceeds</div>

Unless otherwise set forth in a prospectus supplement,
we intend to use the net proceeds from the offering of securities by us under this prospectus for general corporate purposes, including
funding acquisitions, repayment of indebtedness and working capital. Further details relating to the use of the net proceeds from the
offering of securities under this prospectus will be set forth in the applicable prospectus supplement.

| 7 |

<div align='center'>Description
of Capital Stock</div>

Although the following summary describes the material
terms of our capital stock, it is not a complete description of Maryland law or of our charter and bylaws, which are incorporated herein
by reference to the Company’s SEC filings. See “Where You Can